Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

Diversification in the boardroom improves the quality of board performance, encourages objectivity, and expands the quality of debate and decision making. Biopharmaceutical industry boardrooms are ...

Leading a biotech company in this dynamic industry requires a strong, agile team and a championship mindset. Applying the same strategies that led my Philadelphia Eagles to the Superbowl, just as a ...

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO Stefan König.

Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order. That doesnt mean biopharmaceutical companies can backslide on compliance ...

Restructurings and workforce reductions can evoke fear and anxiety among employees, harming productivity. Uncertain times, however, can also provide unique situational opportunities for innovation, ...

NORDs president and CEO, Peter Saltonstall, offers details on the organizations current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.

Through the boom and bust of anti-aging buzz cycles, Life Biosciences has continued its focus on epigenetic reprogramming with an increasingly focused pipeline and development strategy.

James Sapirstein, CEO at Entero Therapeutics and a 40-year biopharmaceutical industry veteran, makes a compelling case for Big Pharma partners and investors to take a chance on a cheap and safe ...